Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2025)

Anaptysbio (ANAB) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $50.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 14.92% year-over-year to $50.7 million, compared with a TTM value of $50.7 million through Dec 2025, down 14.92%, and an annual FY2025 reading of $50.7 million, down 14.92% over the prior year.
  • Total Non-Current Liabilities was $50.7 million for Q4 2025 at Anaptysbio, roughly flat from $50.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $305.9 million in Q3 2022 and bottomed at $35.5 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $65.4 million, with a median of $53.2 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities surged 79.35% in 2021, then crashed 81.8% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $35.5 million in 2021, then rose by 23.4% to $43.9 million in 2022, then grew by 21.91% to $53.5 million in 2023, then increased by 11.33% to $59.5 million in 2024, then decreased by 14.92% to $50.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ANAB at $50.7 million in Q4 2025, $50.7 million in Q3 2025, and $48.6 million in Q2 2025.